Syndax Pharmaceuticals, Inc., a prominent player in the biotechnology sector, has been making significant strides in the healthcare industry with its focus on developing therapies for various cancers. As of October 26, 2025, the company’s stock is trading at $13.11 on the Nasdaq, reflecting a notable fluctuation over the past year. The stock reached its 52-week high of $22.50 on November 10, 2024, and its 52-week low of $8.58 on May 14, 2025. Despite these fluctuations, Syndax Pharmaceuticals maintains a market capitalization of $1.15 billion.

Founded with an Initial Public Offering (IPO) on March 3, 2016, Syndax Pharmaceuticals has established itself as a key entity in the biopharmaceutical landscape. The company is dedicated to advancing therapies for solid tumors and cancers affecting the lung, breast, and hematological systems. Its efforts are primarily directed towards serving the medical and healthcare sectors within the United States.

The company’s financial metrics reveal a Price Earnings (P/E) ratio of -3.58, indicating that it is currently not generating net income. This is not uncommon for biopharmaceutical companies, which often invest heavily in research and development before achieving profitability. Syndax Pharmaceuticals continues to invest in its pipeline of innovative therapies, aiming to address unmet medical needs in oncology.

For those interested in learning more about Syndax Pharmaceuticals and its therapeutic developments, additional information is available on their official website, www.syndax.com . The company remains committed to its mission of providing effective cancer treatments, leveraging its expertise in biotechnology to make meaningful contributions to healthcare.